Online registration is now closed, there will be a limited number of onsite registrations on Monday

The convergence between digital health and the life sciences is creating new opportunities to transform patient care as well as drug discovery and development. From wearables to machine learning, digital technologies are easing data collection from patients, increasing medical adherence, reshaping clinical trials, and offering new insights into real-world applications of therapies. Embedding digital health tools into the life sciences will also allow new therapies to better work within the growing value-based healthcare system that relies on data and measurable outcomes.

Join MassBio for our inaugural Digital Health Impact 2019 event at the InterContinental Boston at 510 Atlantic Ave, Boston, MA 02210, part of Biotech Week Boston, as we examine the current state of digital health as it relates to the life sciences, the challenges facing its growth, and opportunities for collaboration. Through keynotes, panel discussions, and case studies, we’ll explore new strategies for life sciences and digital health innovators to converge and ultimately deliver better outcomes for patients. Contact Laura Rudberg for sponsorship opportunities. View our sponsorship prospectus here

General Manager, ConvergeHEALTH by Deloitte
Brett Davis is a Principal in Deloitte’s Life Sciences and Healthcare consulting practice and General Manager of ConvergeHEALTH by Deloitte, a business unit focused on supporting the information based transformation of healthcare and life sciences. In this role he is responsible for managing Deloitte’s $150M+ investment in new digital engagement and advanced analytics platforms to support the industry’s shift to value based, personalized healthcare. ConvergeHEALTH’s platforms are supporting organizations and patients in over 20 countries globally. In addition to his role at Deloitte, Davis serves on the External Advisory Boards of the Jefferson School of Population Health and the University of Pennsylvania’s Department of Medical Ethics and Health Policy. Previously he served as a Board member of the Personalized Medicine Coalition for 6 years, and as an external advisor to the Ben and Catherine Ivy Cancer Foundation.

Brought to you by